Genitourinary Cancers

A panel of experts detail updated data and developments in the advanced renal cell carcinoma space with immunotherapy-based combination regimens.

Alan Tan, MD, discusses the nuances of navigating combination regimens for patients with advanced renal cell carcinoma.

Chad Tang, MD, discusses unanswered questions surrounding the role of radiation therapy in renal cell carcinoma.

Chad Tang, MD, discusses how radiation could play a role in advanced renal cell carcinoma.

NKT2152, a novel HIF2α inhibitor, produced responses in heavily pretreated advanced clear cell renal cell carcinoma.

Martin H. Voss, MD, discusses the clinical significance of the phase 3 KEYNOTE-564 trial in clear cell renal cell carcinoma.

Martin H. Voss, MD, discusses the evaluation of nivolumab plus ipilimumab in IMDC-classified intermediate/poor-risk renal cell carcinoma.

Research from Dana-Farber Cancer Institute clinicians showed that adding nivolumab to tivozanib did not improve survival for patients with advanced RCC.

The addition of fecal microbiota transplantation to pembrolizumab and axitinib raised the efficacy of the combination in metastatic renal cell carcinoma.

Alexandra Drakaki, MD, PhD, discusses nivolumab plus ipilimumab in the treatment of renal cell carcinoma with sarcomatoid differentiation.

Toni K. Choueiri, MD, discusses early findings from a phase 1/2 trial evaluating NKT2152 in previously-treated advanced clear cell renal cell carcinoma.

Detalimogene voraplasmid generated a 71% complete response rate in patients with BCG-unresponsive non–muscle invasive bladder cancer and CIS.

Oncology experts share their key takeaways in genitourinary cancers and recent updates from the 2024 ESMO Congress.

Alexandra Drakaki, MD, PhD, discusses a case study of a patient with refractory metastatic renal cell carcinoma harboring an ALK rearrangement.

Adam Singer, MD, PhD, discusses the lack of clinical benefit for sequential immunotherapy in advanced renal cell carcinoma.

Chad Tang, MD, discusses the potential role for radiation therapy in advanced renal cell carcinoma.

The novel oral HIF2α inhibitor NKT2152 elicited encouraging responses in patients with previously treated advanced clear cell renal cell carcinoma.

Alexandra Drakaki, MD, PhD, discusses key trials that have shaped the treatment paradigm in non–clear cell renal cell carcinoma.

Elevated fucosylation and sialylation of serum proteins were negative prognostic factors in RCC after treatment with nivolumab plus cabozantinib or sunitinib.

Alexandra Drakaki, MD, dives into a case study of a patient with ALK-positive RCC that exemplified the importance of NGS and precision medicine in kidney cancer.

Alexandra Drakaki, MD, PhD, discusses how the classification of subtypes of non–clear cell renal cell carcinoma has evolved in recent years.

Ipilimumab given in combination with nivolumab met the primary end point of 12-month OS rate vs SOC in patients with nccRCC in the SUNNIFORECAST trial.

Benmelstobart plus anlotinib improved PFS, OS, and ORR vs sunitinib in first-line advanced renal cell carcinoma.

Toni Choueiri, MD, discusses findings with tivozanib plus nivolumab in metastatic RCC after progression on an immune checkpoint inhibitor.